Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.

Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.

To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision

To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective excision of a keloid